We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » ClinicalTrials.gov and the New Final Rule (42 CFR Part 11) - Webinar CD/Transcript

Other Options

Audio CD/Transcript - Aug. 2, 2017

$287.00

Audio CD/Transcript - Aug. 2, 2017

$258.00

Audio CD/Transcript - Aug. 2, 2017

$244.00

Audio CD/Transcript - Aug. 2, 2017

$230.00

Audio CD/Transcript - Aug. 2, 2017

$215.00

ClinicalTrials.gov and the New Final Rule (42 CFR Part 11) - Webinar CD/Transcript

$287.00
Webinar Recordings

Product Details

ClinicalTrials.gov and the New Final Rule (42 CFR Part 11): What Strategic Decisions Do You Need to Consider?

Many trial operators are still scratching their heads. After reading and re-reading the 177 pages of 42 CFR Part 11, “Final Rule for Clinical Trials Registration and Results Information,” can you honestly say:

  • You are certain you’re submitting everything it calls for?
  • You are in compliance with all required timelines?
  • You understand what changes under the final reg, and what remains the same?

If the answer is “no” — or even “maybe” — you’re not alone. This new final rule is full of changes large and small.

FDAnews is addressing the confusion with a new training session featuring a leading light of the FDA regulatory bar, Scott Cunningham Esq., translating the knottiest provisions of the final regulation into simple English. Here’s what you’ll discover:

  • The four elements of an “applicable drug clinical trial,” and how the FDA will interpret what these words really mean
  • Who must submit clinical trial results to ClinicalTrials.gov
  • Clinical trial data submissions deadlines
  • The enforcement landscape: What the FDA can do to police non-compliance, and when enforcement might start
  • Deciphering the ClinicalTrials.gov “voluntary submissions” provisions
  • Navigating provisions on “delayed submission” of results to ClinicalTrials.gov
  • FDA proposals for release of de-identified data — current status
  • And much more!

This training session gives you what you need to know — in just 90 minutes. Don’t risk sanctions for non-compliance. Get up to speed before the inspectors come around.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing